Gift to the World – Remedy for High Blood Pressure
Dr. Mark Sircus, Ac., OMD, DM (P)
This is one of the best gifts I can give the world. It is not another treatment for high blood pressure and, thus, cardiovascular disease, but an actual cure.
On November 11th, I published an essay entitled ‘The Main Cause and Treatment Cure for High Blood Pressure.’ It is a scientific theoretical article worth another read but did not include my personal experience. Little did I know that six weeks later, I would reduce my blood pressure (BP) enough to reduce my BP medication by 75 percent. Perhaps in another month or two of my daily cyclodextrin suppositories, I will be 100 percent off.
I was an emergency care case with two almost wholly blocked cardiac arteries seven months ago. My RN sister, after seeing my catheterization results, was surprised they let me out of the hospital. I avoided surgery by diligently using my Natural Allopathic protocol and was doing better.
After 12 weeks on cyclodextrins, administered daily through liquid suppositories, my blood pressure fluctuates slightly around perfect. The cyclodextrins have cleaned out and opened my arteries, creating enough volume in my blood vessels to lower my pressure. It does this by strip-mining cholesterol out of plaque.
Blood Pressure Medications
Blood pressure (BP) medications are some of the most overly prescribed pharmaceuticals, and some think they do more harm than good. Published in JAMA Network Open on Nov. 25, a study found that discontinuing nursing home residents’ BP medications or reducing their dosage by at least 30 percent did not lead to hospitalization for heart attack or stroke after two years, compared with those who continued taking their prescriptions.
Dr. Michelle Odden, an associate professor of epidemiology in the Department of Epidemiology and Population Health at the Stanford University School of Medicine, said, “The side effects of these medications potentially outweigh the benefits of tightly controlled blood pressure. A 2015 investigation found that people with particularly low blood pressure and those taking multiple BP medications faced more than double the risk of death compared with others with high blood pressure, highlighting the dangers of overtreatment in frail populations.
A study published in Circulation Research in October gave a potential reason for why long-term use of renin-angiotensin system (RAS) inhibitors, a commonly prescribed type of BP medication, may lead to kidney damage.
Cyclodextrins for Cardiovascular Disease A Great and Much-Needed Medical Discovery
Modern medicine has made a mockery of common sense—if not of reality itself. It has harmed our population grievously by endlessly promoting absurd drugs and medical practices. Its unwillingness to ever be accountable or transparent is only matched by its overwhelming desire and propensity to lie to the patients it is supposed to serve. Cardiologists, like other doctors, have tunnel vision. They are stubborn, captured, and enslaved by medical authorities who threaten to pull their licenses if they step off the orthodox line. No one in the medical-industrial complex wants patients to know about cyclodextrins and what they can do for heart patients.
Despite all the work and drugs cardiologists apply in the treatment of atherosclerosis, atherosclerotic cardiovascular diseases remain the leading cause of death and disabilities worldwide.
Atherosclerosis is the root cause of atherosclerotic cardiovascular diseases, such as coronary artery disease, ischemic stroke, as well as peripheral artery disease (Lusis, 2000; Tabaei & Tabaee, 2019).
Accordingly, there is an urgent need for novel therapies with cyclodextrins at the top of the list.
Beta-cyclodextrin is a natural sugar-based compound formed from lactobacilli, approved by the FDA, and has been used for decades in low-fat foods. It is also used to help dissolve drugs for delivery to the body. A substance that subsequently turned out to be cyclodextrin was first mentioned by A. Villiers in 1891. From 1 kg of starch, he obtained 3 g of a crystalline substance by treating the starch with Bacillus amylobacter.
The intensive work on the production of cyclodextrins and their separation into pure fractions subsequently led to the discovery of cyclodextrins with more than eight glucose units. The first patent application describing the ability of cyclodextrins to form complexes was filed in 1953.
In the patent specification, the three scientists, K. Freudenberg, F. Cramer, and H. Plieninger, reported that molecules could be complexed with cyclodextrins and thus be effectively protected from atmospheric oxidation. In addition, they claimed that the solubility of pharmaceutical substances could be increased by complexation, while the vapor pressure of readily volatile substances could be reduced.
The history of cyclodextrins can be divided into three periods, which reflect the different stages in the development of cyclodextrins research.
After their discovery, basic research was carried out from 1891 to 1935, with the molecular structure of cyclodextrins remaining undiscovered for several decades. The discovery in 1936 that they had a cyclic structure composed of glucose units ushered in the following research period, during which they were systematically studied.
Much time was also devoted to researching cyclodextrin complexes. Towards the end of the 1960s, the production of cyclodextrins had been so thoroughly researched that industrial production could begin. The third period, which is still ongoing, is characterized by the evolution of cyclodextrins from expensive fine chemicals to industrial-scale products and their use in various applications.
One study comprehensively analyzes the cholesterol binding mechanism and conformational changes in cyclodextrin (CD). The results revealed that cholesterol binding to CDs was spontaneous and thermodynamically favorable. Controlling cholesterol levels in the body is paramount for maintaining overall health.